Current and historical daily PE Ratio for TG Therapeutics Inc (
STU:NKB2
) from 2015 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. TG Therapeutics stock (STU:NKB2) PE ratio as of May 28 2024 is 75.95.
More Details
TG Therapeutics Inc (STU:NKB2) PE Ratio (TTM) Chart
TG Therapeutics Inc (STU:NKB2) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1235
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| TG Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-28 | 71.6 | 2024-03-21 | 884.7 |
| 2024-05-27 | 71.6 | 2024-03-20 | 856.3 |
| 2024-05-24 | 71.4 | 2024-03-19 | 877.5 |
| 2024-05-23 | 73.5 | 2024-03-18 | 859.4 |
| 2024-05-22 | 70.6 | 2024-03-15 | 882.5 |
| 2024-05-21 | 70.2 | 2024-03-14 | 892.2 |
| 2024-05-20 | 69.9 | 2024-03-13 | 887.2 |
| 2024-05-17 | 70.3 | 2024-03-12 | 900.9 |
| 2024-05-16 | 74.8 | 2024-03-11 | 952.5 |
| 2024-05-15 | 75.8 | 2024-03-08 | 959.1 |
| 2024-05-14 | 77.1 | 2024-03-07 | NaN |
| 2024-05-13 | 75.1 | 2024-03-06 | NaN |
| 2024-05-10 | 72.5 | 2024-03-05 | NaN |
| 2024-05-09 | 74.3 | 2024-03-04 | NaN |
| 2024-05-08 | 74.0 | 2024-03-01 | 984.4 |
| 2024-05-07 | 71.0 | 2024-02-29 | NaN |
| 2024-05-06 | 69.3 | 2024-02-28 | NaN |
| 2024-05-03 | 70.1 | 2024-02-27 | 763.8 |
| 2024-05-02 | 69.2 | 2024-02-26 | 768.1 |
| 2024-04-30 | 59.4 | 2024-02-23 | 772.8 |
| 2024-04-29 | 57.6 | 2024-02-22 | 754.7 |
| 2024-04-26 | 58.8 | 2024-02-21 | 755.9 |
| 2024-04-25 | 59.1 | 2024-02-20 | 793.8 |
| 2024-04-24 | 59.8 | 2024-02-19 | 792.5 |
| 2024-04-23 | 62.9 | 2024-02-16 | 801.6 |
| 2024-04-22 | 59.7 | 2024-02-15 | 820.6 |
| 2024-04-19 | 59.5 | 2024-02-14 | 813.8 |
| 2024-04-18 | 61.1 | 2024-02-13 | 869.4 |
| 2024-04-17 | 59.4 | 2024-02-12 | 863.8 |
| 2024-04-16 | 61.2 | 2024-02-09 | 854.1 |
| 2024-04-15 | 61.8 | 2024-02-08 | 844.1 |
| 2024-04-12 | 62.0 | 2024-02-07 | 836.9 |
| 2024-04-11 | 63.8 | 2024-02-06 | 884.1 |
| 2024-04-10 | 63.0 | 2024-02-05 | 947.2 |
| 2024-04-09 | 65.4 | 2024-02-02 | 964.4 |
| 2024-04-08 | 62.9 | 2024-02-01 | 940.6 |
| 2024-04-05 | 61.8 | 2024-01-31 | 923.4 |
| 2024-04-04 | 61.7 | 2024-01-30 | 923.4 |
| 2024-04-03 | 61.6 | 2024-01-29 | 896.9 |
| 2024-04-02 | 63.6 | 2024-01-26 | 915.9 |
| 2024-03-28 | 67.5 | 2024-01-25 | 915.9 |
| 2024-03-27 | 893.4 | 2024-01-24 | 899.7 |
| 2024-03-26 | 877.8 | 2024-01-23 | 902.5 |
| 2024-03-25 | 897.8 | 2024-01-22 | 890.0 |
| 2024-03-22 | 893.1 | 2024-01-19 | 861.6 |
TG Therapeutics Inc (STU:NKB2) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
STU:NKB2: Ordinary SharesDescription
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers